Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization Platform
Collaboration Provides Axsome Access to New Digital Technologies Developed by Veeva
Axsome Therapeutics, Inc. , a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, and Veeva Systems, announced a strategic partnership to augment the build of Axsome’s Digital-Centric Commercialization (DCC™) platform. Veeva is the leader in cloud solutions for the global life sciences industry.
Axsome and Veeva form strategic partnership to augment the build of Axsome’s Digital-Centric Commercialization (DCC) platform. Axsome will use all Veeva Commercial Cloud products, including multichannel Veeva CRM, MyVeeva for Doctors, and Veeva Data Cloud.
The partnership with Veeva is part of the continuing build of Axsome’s DCC platform in preparation for the potential launch of two differentiated CNS investigational medicines, AXS-05 for depression and AXS-07 for migraine, anticipated next year. The Axsome DCC platform is a proprietary approach to commercialization that incorporates specialized digital tools, proprietary data and analytics, integrated systems, and an intelligent operating model. Through this digital platform, Axsome aims to optimize physician and patient engagements, enhance engagement quality, and increase the effectiveness of promotional efforts as compared to traditional approaches.
Recommended AI News: ICC Partners with GigaIO to Offer NovArray HPC Solution
The Axsome’s DCC platform will utilize all Veeva Commercial Cloud products and services, including: multichannel Veeva CRM as the technology foundation for engagement of customers through preferred digital and personal channels; MyVeeva for Doctors mobile application for healthcare professionals (HCPs) that will allow efficient and compliant real-time messaging between HCPs and Axsome; and Veeva Data Cloud which will provide longitudinal data to power an efficient, targeted launch.
As part of the strategic partnership, Axsome will also have early access to new digital technologies developed by Veeva, and Axsome will help shape Veeva’s product direction. This access will increase the scope of digital tools available to Axsome. In addition, Veeva’s Business Consulting team will provide deep domain expertise and the most complete, industrywide engagement data and insights to support Axsome’s launch strategy.
Recommended AI News: Cryptocurrency Volatility – A Friend Or A Foe
“Veeva is an ideal partner for Axsome as they share our commitment to innovation and passion for improving patient care,” said Herriot Tabuteau, M.D., chief executive officer of Axsome. “This partnership provides us a specialized platform of technology, data, and business consulting to drive our Digital-Centric Commercialization approach for more effective and capital efficient commercial execution.”
“Axsome’s Digital-Centric Commercialization strategy would represent a significant shift for the pharmaceutical industry. We are pleased to partner closely with Axsome to help shape and execute their innovative launch plans,” said Peter Gassner, founder and CEO at Veeva. “We are committed to moving the industry forward by combining the best in technology, data, and business consulting.”
Recommended AI News: CONNECTIONS Conference to Unravel the State of the Smart Home Market in 2020-21